Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles

References

• 1 Xu X, Ho W, Zhang X, Bertrand N, Farokhzad O. Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol. Med. 21(4), 223–232 (2015).
  Medline CASGoogle Scholar
• 2 Jain A, Jain A, Garg NK et al. Surface engineered polymeric nanocarriers mediate the delivery of transferrin–methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater. 24, 140–151 (2015).
  Medline CASGoogle Scholar
• 3 Sperling RA, Parak W. Surface modification, functionalization and bioconjugation of colloidal inorganic nanoparticles. Philosophical Transactions of the Royal Society of London 368(1915), 1333–1383 (2010).
  CASGoogle Scholar
• 4 Thanh NT, Green LA. Functionalisation of nanoparticles for biomedical applications. Nano Today 5(3), 213–230 (2010).
  CASGoogle Scholar
• 5 Chou LY, Ming K, Chan WC. Strategies for the intracellular delivery of nanoparticles. Chem. Soc. Rev. 40(1), 233–245 (2011).
  Medline CASGoogle Scholar
• 6 Alexander-Bryant AA, VB-F WS, Wen X. Bioengineering strategies for designing targeted cancer therapies. Adv. Cancer Res. 118, 1–59 (2012).
  Google Scholar
• 7 Conde J, Dias JT, Grazú V, Moros M, Baptista PV, De La Fuente JM. Revisiting 30 years of biofunctionalization and surface chemistry of inorganic nanoparticles for nanomedicine. Front. Chem. 2, 48 (2014).
  MedlineGoogle Scholar
• 8 Praetorius NP, Mandal TK. Engineered nanoparticles in cancer therapy. Recent Pat. Drug Deliv. Formul. (1), 37–51 (2007).
  MedlineGoogle Scholar
• 9 Almer G, Wernig K, Saba-Lepek M et al. Adiponectin-coated nanoparticles for enhanced imaging of atherosclerotic plaques. Int. J. Nanomed. 6, 1279 (2011).
  Medline CASGoogle Scholar
• 10 Satishkumar R, Vertegel A. Antibody-directed targeting of lysostaphin adsorbed onto polylactide nanoparticles increases its antimicrobial activity against S. aureus in vitro. Nanotechnology 22(50), 505103 (2011).
  MedlineGoogle Scholar
• 11 Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J. Control. Release 235, 34–47 (2016).
  Medline CASGoogle Scholar
• 12 Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 29(33), 4429–4438 (2008).
  Medline CASGoogle Scholar
• 13 Tosi G, Fano RA, Bondioli L et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood–brain barrier. Nanomedicine 6(3), 423–436 (2011).
  CASGoogle Scholar
• 14 Cardoso MM, Peca NI, Roque ACA. Antibody-conjugated nanoparticles for therapeutic applications. Curr. Med. Chem. 19(19), 3103–3127 (2012).
  Medline CASGoogle Scholar
• 15 Farokhzad OC, Jon S, Khademhosseini A, Tran T-NT, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 64(21), 7668–7672 (2004).
  Medline CASGoogle Scholar
• 16 Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869–876 (2007).
  Medline CASGoogle Scholar
• 17 Pelaz B, Del Pino P, Maffre P et al. Surface functionalization of nanoparticles with polyethylene glycol: effects on protein adsorption and cellular uptake. ACS Nano 9(7), 6996–7008 (2015).
  Medline CASGoogle Scholar
• 18 Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science 263(5153), 1600–1603 (1994).
  Medline CASGoogle Scholar
• 19 Aggarwal P, Hall JB, Mcleland CB, Dobrovolskaia MA, Mcneil SE. Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv. Drug Deliv. Rev. 61(6), 428–437 (2009).
  Medline CASGoogle Scholar
• 20 Rahman M, Laurent S, Tawil N, Yahia LH, Mahmoudi M. Nanoparticle and protein corona. Int. J. Nanomedicine 15, 21–44 (2013).
  Google Scholar
• 21 Hu W, Peng C, Lv M et al. Protein corona-mediated mitigation of cytotoxicity of graphene oxide. ACS Nano 5(5), 3693–3700 (2011).
  Medline CASGoogle Scholar
• 22 Lee YK, Choi EJ, Webster TJ, Kim SH, Khang D. Effect of the protein corona on nanoparticles for modulating cytotoxicity and immunotoxicity. Int. J. Nanomedicine 10, 97–113 (2015).
  MedlineGoogle Scholar
• 23 Monopoli MP, Walczyk D, Campbell A et al. Physical-chemical aspects of protein corona: relevance to in vitro and in vivo biological impacts of nanoparticles. J. Am. Chem. Soc. 133(8), 2525–2534 (2011).
  Medline CASGoogle Scholar
• 24 Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release 161(2), 505–522 (2012).
  Medline CASGoogle Scholar
• 25 Costantino L, Gandolfi F, Tosi G, Rivasi F, Vandelli MA, Forni F. Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier. J. Control. Release 108(1), 84–96 (2005).
  Medline CASGoogle Scholar
• 26 Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 312(5990), 162–163 (1984).
  Medline CASGoogle Scholar
• 27 Tosi G, Vilella A, Chhabra R et al. Insight on the fate of CNS-targeted nanoparticles. Part II: intercellular neuronal cell-to-cell transport. J. Control. Release 177(Suppl. C), 96–107 (2014).
  Medline CASGoogle Scholar
• 28 Vergoni AV, Tosi G, Tacchi R, Vandelli MA, Bertolini A, Costantino L. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution. Nanomed. Nanotechnol. Biol. Med. 5(4), 369–377 (2009).
  CASGoogle Scholar
• 29 Valenza M, Chen JY, Di Paolo E et al. Cholesterol-loaded nanoparticles ameliorate synaptic and cognitive function in Huntington's disease mice. EMBO Mol. Med. 7(12), 1547–1564 (2015).
  Medline CASGoogle Scholar
• 30 Posadas I, Monteagudo S, Cena V. Nanoparticles for brain-specific drug and genetic material delivery, imaging and diagnosis. Nanomedicine (Lond.) 11(7), 833–849 (2016).
  CASGoogle Scholar
• 31 Salvalaio M, Rigon L, Belletti D et al. Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders. PLoS ONE 11(5), e0156452 (2016).
  MedlineGoogle Scholar
• 32 Grabrucker AM, Garner CC, Boeckers TM et al. Development of novel Zn2+ loaded nanoparticles designed for cell-type targeted drug release in CNS neurons: in vitro evidences. PLoS ONE 6(3), e17851 (2011).
  Medline CASGoogle Scholar
• 33 Monsalve Y, Tosi G, Ruozi B et al. PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine (Lond.) 10(11), 1735–1750 (2015).
  CASGoogle Scholar
• 34 Tang X, Liang Y, Zhu Y et al. Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicity. Int. J. Nanomedicine 10, 6227–6241 (2015).
  Medline CASGoogle Scholar
• 35 Aktas Y, Yemisci M, Andrieux K et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug. Chem. 16(6), 1503–1511 (2005).
  Medline CASGoogle Scholar
• 36 Loureiro JA, Gomes B, Fricker G, Coelho MAN, Rocha S, Pereira MC. Cellular uptake of PLGA nanoparticles targeted with anti-amyloid and anti-transferrin receptor antibodies for Alzheimer's disease treatment. Colloids Surf. B. Biointerfaces 145, 8–13 (2016).
  Medline CASGoogle Scholar
• 37 Schnyder A, Krähenbühl S, Drewe J, Huwyler J. Targeting of daunomycin using biotinylated immunoliposomes: pharmacokinetics, tissue distribution and in vitro pharmacological effects. J. Drug Targeting 13(5), 325–335 (2005).
  Medline CASGoogle Scholar
• 38 Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J. Cereb. Blood Flow Metab. 24(11), 1193–1204 (2004).
  Medline CASGoogle Scholar
• 39 Georgieva JV, Hoekstra D, Zuhorn IS. Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood–brain barrier. Pharmaceutics 6(4), 557–583 (2014).
  Medline CASGoogle Scholar
• 40 Feliu N, Docter D, Heine M et al. In vivo degeneration and the fate of inorganic nanoparticles. Chem. Soc. Rev. 45(9), 2440–2457 (2016).
  Medline CASGoogle Scholar
• 41 Walkey CD, Olsen JB, Song F et al. Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles. ACS Nano 8(3), 2439–2455 (2014).
  Medline CASGoogle Scholar
• 42 Monopoli MP, Pitek AS, Lynch I, Dawson KA. Formation and characterization of the nanoparticle-protein corona. Methods Mol. Biol. 1025, 137–155 (2013).
  Medline CASGoogle Scholar
• 43 Setyawati MI, Tay CY, Docter D, Stauber RH, Leong DT. Understanding and exploiting nanoparticles’ intimacy with the blood vessel and blood. Chem. Soc. Rev. 44(22), 8174–8199 (2015).
  Medline CASGoogle Scholar
• 44 Tenzer S, Docter D, Kuharev J et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat. Nanotechnol. 8(10), 772–781 (2013).
  Medline CASGoogle Scholar
• 45 Walkey CD, Olsen JB, Guo H, Emili A, Chan WC. Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. J. Am. Chem. Soc. 134(4), 2139–2147 (2012).
  Medline CASGoogle Scholar
• 46 Sempf K, Arrey T, Gelperina S et al. Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur. J. Pharm. Biopharm. 85(1), 53–60 (2013).
  Medline CASGoogle Scholar
• 47 Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int. J. Pharm. 55(1), R1–R4 (1989).
  CASGoogle Scholar
• 48 Joshi D, Lan-Chun-Fung Y, Pritchard J. Determination of poly (vinyl alcohol) via its complex with boric acid and iodine. Anal. Chim. Acta 104(1), 153–160 (1979).
  CASGoogle Scholar
• 49 Cedervall T, Lynch I, Lindman S et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2050–2055 (2007).
  Medline CASGoogle Scholar
• 50 Chambers MC, Maclean B, Burke R et al. A cross-platform toolkit for mass spectrometry and proteomics. Nat. Biotechnol. 30(10), 918–920 (2012).
  Medline CASGoogle Scholar
• 51 Zambaux M, Bonneaux F, Gref R et al. Influence of experimental parameters on the characteristics of poly (lactic acid) nanoparticles prepared by a double emulsion method. J. Control. Release 50(1), 31–40 (1998).
  Medline CASGoogle Scholar
• 52 Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240(4852), 622–630 (1988).
  Medline CASGoogle Scholar
• 53 Nadal A, Fuentes E, Pastor J, Mcnaughton PA. Plasma albumin is a potent trigger of calcium signals and DNA synthesis in astrocytes. Proc. Natl Acad. Sci. USA 92(5), 1426–1430 (1995).
  Medline CASGoogle Scholar
• 54 Meister S, Zlatev I, Stab J et al. Nanoparticulate flurbiprofen reduces amyloid-β42 generation in an in vitro blood–brain barrier model. Alzheimers Res. Ther. 5(6), 51 (2013).
  MedlineGoogle Scholar
• 55 Ritz S, Schottler S, Kotman N et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules 16(4), 1311–1321 (2015).
  Medline CASGoogle Scholar
• 56 Nguyen VH, Lee BJ. Protein corona: a new approach for nanomedicine design. Int. J. Nanomedicine 12, 3137–3151 (2017).
  Medline CASGoogle Scholar
• 57 Kim HR, Andrieux K, Delomenie C et al. Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis 28(13), 2252–2261 (2007).
  Medline CASGoogle Scholar
• 58 Klein J. Probing the interactions of proteins and nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2029–2030 (2007).
  Medline CASGoogle Scholar
• 59 Gessner A, Lieske A, Paulke BR, Müller RH. Functional groups on polystyrene model nanoparticles: influence on protein adsorption. J. Biomed. Mater. Res. 65(3), 319–326 (2003).
  MedlineGoogle Scholar
• 60 Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem. Soc. Rev. 41(7), 2780–2799 (2012).
  Medline CASGoogle Scholar
• 61 Fisher CA, Narayanaswami V, Ryan RO. The lipid-associated conformation of the low density lipoprotein receptor binding domain of human apolipoprotein E. J. Biol. Chem. 275(43), 33601–33606 (2000).
  Medline CASGoogle Scholar
• 62 Gupta V, Narayanaswami V, Budamagunta MS, Yamamato T, Voss JC, Ryan RO. Lipid-induced extension of apolipoprotein E helix 4 correlates with low density lipoprotein receptor binding ability. J. Biol. Chem. 281(51), 39294–39299 (2006).
  Medline CASGoogle Scholar
• 63 Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. Mol. Cell. Ther. 4, 3 (2016).
  MedlineGoogle Scholar
• 64 Wolfram J, Yang Y, Shen J et al. The nano-plasma interface: implications of the protein corona. Colloids Surf. B Biointerfaces 124, 17–24 (2014).
  Medline CASGoogle Scholar
• 65 Wang F, Yu L, Monopoli MP et al. The biomolecular corona is retained during nanoparticle uptake and protects the cells from the damage induced by cationic nanoparticles until degraded in the lysosomes. Nanomed. Nanotechnol. Biol. Med. 9(8), 1159–1168 (2013).
  CASGoogle Scholar
• 66 Docter D, Westmeier D, Markiewicz M, Stolte S, Knauer SK, Stauber RH. The nanoparticle biomolecule corona: lessons learned – challenge accepted? Chem. Soc. Rev. 44(17), 6094–6121 (2015).
  Medline CASGoogle Scholar
• 67 Pederzoli F, Tosi G, Vandelli MA, Belletti D, Forni F, Ruozi B. Protein corona and nanoparticles: how can we investigate on? Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. doi:10.1002/wnan.1467 (2017) (Epub ahead of print).
  MedlineGoogle Scholar
• 68 Ashby J, Pan S, Zhong W. Size and surface functionalization of iron oxide nanoparticles influence the composition and dynamic nature of their protein corona. ACS Appl. Mater. Interfaces 6(17), 15412–15419 (2014).
  Medline CASGoogle Scholar
• 69 Kreuter J, Shamenkov D, Petrov V et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood–brain barrier. J. Drug Targeting 10(4), 317–325 (2002).
  Medline CASGoogle Scholar
• 70 Goppert TM, Muller RH. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 60(3), 361–372 (2005).
  MedlineGoogle Scholar
• 71 Michaelis K, Hoffmann M, Dreis S et al. Covalent linkage of apolipoprotein E to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317(3), 1246–1253 (2006).
  Medline CASGoogle Scholar
• 72 Dal Magro R, Ornaghi F, Cambianica I et al. ApoE-modified solid lipid nanoparticles: a feasible strategy to cross the blood–brain barrier. J. Control. Release 249, 103–110 (2017).
  Medline CASGoogle Scholar
• 73 Peng Q, Zhang S, Yang Q et al. Preformed albumin corona, a protective coating for nanoparticles based drug delivery system. Biomaterials 34(33), 8521–8530 (2013).
  Medline CASGoogle Scholar
• 74 Owens DE, Peppas NA. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 307(1), 93–102 (2006).
  Medline CASGoogle Scholar
• 75 Chang J, Jallouli Y, Kroubi M et al. Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood–brain barrier. Int. J. Pharm. 379(2), 285–292 (2009).
  Medline CASGoogle Scholar